Global Cholangiopancreatography Device Market Size By Type (Mechanical, Electronic), By Application (Hospital, Medical Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Cholangiopancreatography Device Market was valued at USD 812 million in 2023 and is projected to reach USD 1.42 billion by 2031, growing at a CAGR of 7.2% from 2023 to 2031. This market is driven by the rising incidence of biliary and pancreatic disorders, increasing demand for minimally invasive diagnostic and therapeutic procedures, and advancements in endoscopic and imaging technologies. Cholangiopancreatography devices, including ERCP (Endoscopic Retrograde Cholangiopancreatography) and MRCP (Magnetic Resonance Cholangiopancreatography) tools, are essential in diagnosing and treating conditions such as gallstones, strictures, and pancreatic duct abnormalities.

Drivers

1. Growing Prevalence of Biliary and Pancreatic Diseases

The increasing global burden of conditions like gallstones, pancreatitis, and cholangiocarcinoma is propelling the demand for accurate diagnostic modalities such as ERCP and MRCP. Aging populations and dietary changes are contributing significantly to these disorders.

2. Technological Advancements in Imaging and Endoscopy

Innovations such as high-definition endoscopic imaging, digital cholangioscopy, and contrast-enhanced MRI are improving diagnostic precision and procedural safety, expanding the market potential for cholangiopancreatography devices.

3. Surge in Demand for Minimally Invasive Procedures

Patients and providers prefer endoscopic techniques over surgical methods due to faster recovery, lower risk, and reduced hospital stay, boosting the adoption of ERCP and MRCP devices worldwide.

Restraints

1. High Cost of Advanced Imaging Equipment

The high upfront cost of devices and the ongoing maintenance required, particularly for MRCP equipment, can hinder market growth, especially in low-income and resource-limited settings.

2. Risk of Procedure-related Complications

Although minimally invasive, ERCP procedures carry risks such as pancreatitis, infections, or bleeding, which can deter both patients and healthcare professionals from widespread adoption.

Opportunity

1. Expanding Healthcare Infrastructure in Emerging Economies

Rising investments in healthcare across Asia-Pacific, Latin America, and parts of the Middle East and Africa are expected to create significant opportunities for cholangiopancreatography device manufacturers.

2. Integration of AI in Diagnostic Imaging

Artificial Intelligence (AI) is increasingly being integrated into imaging platforms, enabling enhanced diagnostics, image interpretation, and procedural planning. This offers strong potential for innovation in MRCP-based devices.

Market by System Type Insights

The ERCP Devices segment accounted for the largest market share in 2023. These devices remain the gold standard for both diagnostic and therapeutic interventions in pancreatobiliary disorders. However, the MRCP Devices segment is expected to grow at the fastest rate due to its non-invasive nature and increasing integration with AI-powered imaging systems, especially in outpatient settings.

Market by End-use Insights

Hospitals emerged as the leading end-use segment, holding more than 55% of the total market revenue in 2023. Their advanced infrastructure and higher procedural volumes account for this dominance. Ambulatory Surgical Centers (ASCs) are projected to witness robust growth, driven by a preference for outpatient, cost-effective, and minimally invasive care.

Market by Regional Insights

North America led the global market in 2023, supported by high healthcare expenditure, technological leadership, and favorable reimbursement policies. Asia-Pacific is expected to register the highest CAGR through 2031, owing to expanding access to healthcare, rising incidence of biliary diseases, and rapid adoption of advanced medical technologies in countries such as China, India, and South Korea.

Competitive Scenario

Key players in the Global Cholangiopancreatography Device Market include:

Boston Scientific Corporation

Olympus Corporation

Medtronic Plc

Cook Medical

Fujifilm Holdings Corporation

Becton, Dickinson and Company

CONMED Corporation

Hoya Corporation (Pentax Medical)

Taewoong Medical Co., Ltd.

Karl Storz SE & Co. KG

These companies are focusing on technological innovations, AI integration, and strategic collaborations to enhance their global footprint. For instance:

In 2024, Olympus introduced an AI-assisted ERCP system designed to improve procedural efficiency and accuracy.

Boston Scientific expanded its range of digital cholangioscopes in 2023, offering real-time HD visualization capabilities.

Scope of Work – Global Cholangiopancreatography Device Market

Report Metric Details

Market Size (2023) USD 812 million

Projected Market Size (2031) USD 1.42 billion

CAGR (2023–2031) 7.2%

Market Segments System Type (ERCP, MRCP), End-use (Hospitals, ASCs, Clinics), Region

Growth Drivers Rising incidence of biliary disorders, demand for minimally invasive diagnostics, technological innovation

Opportunities AI-powered imaging, expansion in emerging markets

Key Market Developments

2023: Boston Scientific launched a next-gen digital cholangioscope with enhanced imaging and maneuverability features.

2024: Olympus unveiled an AI-assisted navigation platform for ERCP procedures, aimed at increasing success rates and reducing complications.

2025: Cook Medical announced a partnership with a leading diagnostic AI firm to integrate real-time decision support into cholangiopancreatography systems.

FAQs

1) What is the current market size of the Global Cholangiopancreatography Device Market?

The market was valued at USD 812 million in 2023.

2) What is the major growth driver of the Global Cholangiopancreatography Device Market?

The primary growth drivers include the